JPS62155264A - 新規安定化ベンズイミダゾ−ル誘導体 - Google Patents

新規安定化ベンズイミダゾ−ル誘導体

Info

Publication number
JPS62155264A
JPS62155264A JP61283015A JP28301586A JPS62155264A JP S62155264 A JPS62155264 A JP S62155264A JP 61283015 A JP61283015 A JP 61283015A JP 28301586 A JP28301586 A JP 28301586A JP S62155264 A JPS62155264 A JP S62155264A
Authority
JP
Japan
Prior art keywords
formula
amorphous
lower alkyl
compound
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP61283015A
Other languages
English (en)
Japanese (ja)
Inventor
リチャード・アレン・ランケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of JPS62155264A publication Critical patent/JPS62155264A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP61283015A 1985-11-27 1986-11-26 新規安定化ベンズイミダゾ−ル誘導体 Pending JPS62155264A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80250885A 1985-11-27 1985-11-27
US802508 1985-11-27

Publications (1)

Publication Number Publication Date
JPS62155264A true JPS62155264A (ja) 1987-07-10

Family

ID=25183897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61283015A Pending JPS62155264A (ja) 1985-11-27 1986-11-26 新規安定化ベンズイミダゾ−ル誘導体

Country Status (14)

Country Link
EP (1) EP0224257A1 (enExample)
JP (1) JPS62155264A (enExample)
CN (1) CN86108096A (enExample)
AU (1) AU6569986A (enExample)
BR (1) BR8605798A (enExample)
DD (1) DD252540A5 (enExample)
DK (1) DK569686A (enExample)
FI (1) FI864813A7 (enExample)
HU (1) HU198025B (enExample)
IL (1) IL80768A0 (enExample)
IN (1) IN164294B (enExample)
NO (1) NO864740D0 (enExample)
PT (1) PT83811B (enExample)
ZA (1) ZA868962B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102452987A (zh) * 2010-10-28 2012-05-16 桂林南药股份有限公司 一种不定形晶型阿苯达唑的制备方法
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS601101A (ja) * 1983-06-15 1985-01-07 Yuukou Yakuhin Kogyo Kk 水性懸濁農薬製剤
DE3347579A1 (de) * 1983-12-30 1985-07-11 Hoechst Ag, 6230 Frankfurt Zubereitungen schwer wasserloeslicher anthelminthika und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
IN164294B (enExample) 1989-02-11
EP0224257A1 (en) 1987-06-03
DK569686D0 (da) 1986-11-26
AU6569986A (en) 1987-06-04
HU198025B (en) 1989-07-28
BR8605798A (pt) 1987-08-25
FI864813A0 (fi) 1986-11-26
HUT42076A (en) 1987-06-29
FI864813A7 (fi) 1987-05-28
NO864740D0 (no) 1986-11-26
PT83811B (en) 1988-03-15
IL80768A0 (en) 1987-02-27
DD252540A5 (de) 1987-12-23
CN86108096A (zh) 1987-07-08
ZA868962B (en) 1988-07-27
PT83811A (en) 1986-12-01
DK569686A (da) 1987-05-28

Similar Documents

Publication Publication Date Title
JP6612200B2 (ja) 抗炎症性の置換シクロブテンジオン化合物のコリン塩
JP5671560B2 (ja) 固体投与形中のテトラサイクリン金属錯体
US20110070303A1 (en) Novel dosage formulation
WO2022171150A1 (en) Methods and pharmaceutical composition for treating diseases
KR101047042B1 (ko) 생체이용율을 향상시킨 경구용 제제
CN111514142B (zh) 含硝羟喹啉前药的药物组合物及其制备方法和应用
CN105050585A (zh) 稳定的葡萄糖激酶活化剂组合物
JPS62155263A (ja) アモルフアス−ベンズイミダゾ−ル誘導体
JPS62155264A (ja) 新規安定化ベンズイミダゾ−ル誘導体
CN1468231A (zh) 细胞周期抑制剂的无定形形式
CN110035750B (zh) 药物组合物和使用方法
CN107789321A (zh) 一种提高溶水性的阿莫西林可溶性粉
CN117899084A (zh) 药物组合物、制剂、美托拉宗冻干粉制剂及其制备方法与用途
TW202019416A (zh) 乙內醯脲衍生物的固體分散體
CN112574160A (zh) 一种高良姜素衍生物及其制备方法和应用
WO2021226738A1 (zh) 包含仑伐替尼的分子水平的药物组合物及其制备方法和应用
NO880083L (no) Fremgangsmaate for fremstilling av amorfe benzimidazolderivater med forbedret opploeselighet og anthelmintisk aktivitet.
CN103664930B (zh) 一类含噻唑结构的化合物、其制备方法和用途
CN104892524B (zh) 芬苯达唑微晶体的制备方法
NO881861L (no) Fremgangsmaate for fremstilling av amorfe benzimidazolderivater med forbedret opploeselighet og anthelmintisk aktivitet.
EP4309648A1 (en) Lacosamide pharmaceutical composition, preparation method for same, and applications thereof
NO881787L (no) Fremgangsmaate for femstilling av amorfe benzimidazolderivater med fobedret opploeselighet og anthelmintisk aktivitet.
NO881862L (no) Fremgangsmaate for fremstilling av amorfe benzimidazolderivater med forbedret opploeselighet og anthelmintisk aktivitet.
NO881788L (no) Fremgangsmaate for fremstilling av amorfe benzimidazolderivater med forbedret opploeselighet og anthelmintisk aktivitet.
CN110563668A (zh) 控制硝唑尼特粒度的结晶方法及其应用